Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 137-139

  Chua, Terence C ^a   Liauw, Winston ^a   Robertson, Greg ^a   Chia, Whay Kuang John ^b   Soo, Khee Chee ^b   AlObaid, Abdulaziz ^c   Al Mohaimeed, Khaled ^c   Morris, David L ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; HYPERTHERMIC THERAPY; LAPAROTOMY; LETTER; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL TIME;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; OVARIAN NEOPLASMS; PERITONEUM; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67349137391     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.002     Document Type: Letter

References (14)

1. Markman M. Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluation. Gynecol. Oncol. (2009)
2. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al., The Gynecologic Oncology G. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
3. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
4. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
5. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J.M., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 100 (2006) 27-32
6. Walker J.L. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol. Oncol. 112 (2009) 439-440
7. Bristow R.E., Puri I., and Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112 (2009) 265-274
8. Spratt J.S., Adcock R.A., Muskovin M., Sherrill W., and Mckeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 40 (1980) 256-260
9. Sugarbaker P.H. Peritonectomy procedures. Ann. Surg. 221 (1995) 29-42
10. Sugarbaker P. Peritoneal Carcinomatosis: Drugs and Diseases (1996), Kluwer, Boston
11. Glehen O., Mohamed F., and Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 5 (2004) 219-228
12. Verwaal V.J., van Ruth S., de Bree E., van Sloothen G.W., van Tinteren H., Boot H., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21 (2003) 3737-3743
13. Bereder J.M. HIPEC in ovarian cancer - French experience. 6th Workshop on Peritoneal Surface Oncology (2008), Lyon
14. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108